

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:41:38 ON 23 APR 2008

FILE 'REGISTRY' ENTERED AT 10:42:15 ON 23 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 APR 2008 HIGHEST RN 1016649-50-5
DICTIONARY FILE UPDATES: 22 APR 2008 HIGHEST RN 1016649-50-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10667111.str



chain nodes :

15 18

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

9-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 7-14 8-9 9-10 11-12 12-13
13-14

exact

8-9 9-10 9-15

exact bonds :

5-7 6-10 7-

normalized bonds :

10/ 667,111

1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 18:CLASS 19:Atom

L1 STRUCTURE UPLOADED

=> L1


L1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:42:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 187 TO 773

PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s 11 ful

FULL SEARCH INITIATED 10:42:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 393 TO ITERATE

100.0% PROCESSED 393 ITERATIONS

87 ANSWERS

SEARCH TIME: 00.00.01

L3 87 SEA SSS FUL L1

```
=> file caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY          SESSION
FULL ESTIMATED COST          178.36          178.57
```

FILE 'CAPLUS' ENTERED AT 10:42:56 ON 23 APR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Apr 2008 VOL 148 ISS 17
 FILE LAST UPDATED: 22 Apr 2008 (20080422/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s 13
L4          8 L3
```


```
=> d 14 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y
```

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:619774 CAPLUS
 DOCUMENT NUMBER: 147:52915
 TITLE: Preparation of spiro-cyclic quinazoline derivatives as phosphodiesterase inhibitors and antiviral agents
 INVENTOR(S): Rawson, David James; Swain, Nigel Alan
 PATENT ASSIGNEE(S): Pfizer Limited, UK
 SOURCE: PCT Int. Appl., 110pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063391	A2	20070607	WO 2006-IB3388	20061123
WO 2007063391	A3	20070913		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,				

OTHER SOURCE(S): MARPAT 147:52915

GI



AB Spiro-cyclic quinazoline derivs. I, wherein: n is 0-2; X is O, S, N-CN; R is F, Cl, CN; A is a C3-6 cyclo-alkylene group optionally substituted with a C1-4 alkyl group; and B is a single bond or a C1-2 alkylene group; or a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof for the treatment of diseases or conditions for which therapy by a phosphodiesterase 7 (PDE7) inhibitor is relevant, wherein the disease or condition is selected from pain, T-cell-related diseases, autoimmune diseases, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease, asthma, cancer, acquired immune deficiency syndrome (AIDS), allergy, or inflammatory bowel disease. The compds. are PDE7 inhibitors and have a number of therapeutic applications, particularly in the treatment of pain, especially neuropathic pain. Thus, title quinazoline II was prepared from 8'-chloro-5'-hydroxy-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one via oxidation of 8'-Chloro-5'-{[cis-3-(hydroxymethyl)cyclobutyl]oxy}-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one with periodic acid.


IT 908570-12-7P 908570-13-8P 939768-47-5P
939768-48-6P 939768-49-7P 939768-50-0P
939768-51-1P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spiro-cyclic quinazoline derivs. as phosphodiesterase inhibitors and antiviral agents)

RN 908570-12-7 CAPLUS
CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, cis-NAME


Relative stereochemistry.



RN 908570-13-8 CAPLUS


CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 939768-47-5 CAPLUS


CN Cyclobutanecarboxylic acid, 3-[[[8'-fluoro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl]oxy]methyl]- (CA INDEX NAME)



RN 939768-48-6 CAPLUS


CN Cyclobutanecarboxylic acid, 3-[(8'-cyano-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 939768-49-7 CAPLUS


CN Cyclobutanecarboxylic acid, 1-[[[8'-fluoro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazoline]-5'-yl]oxy]methyl]- (CA INDEX NAME)



RN 939768-50-0 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[[8'-chloro-2',3'-dihydro-2'-oxospiro[cycloheptane-1,4'(1'H)-quinazoline]-5'-yl]oxy]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 939768-51-1 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclopentane-1,4'(1'H)-quinazolin]-5'-yl]oxy]-, trans- (CA INDEX NAME)

Relative stereochemistry.



IT 939768-70-4 939768-71-5 939768-72-6

939768-73-7

RL: PRP (Properties)

(preparation of spiro-cyclic quinazoline derivs. as phosphodiesterase inhibitors and antiviral agents)

RN 939768-70-4 CAPLUS


CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazoline]-5'-yl]oxy]-, trans-, compd. with N,N-dimethylacetamide (1:2) (CA INDEX NAME)

CM 1

CRN 908570-13-8


CMF C18 H21 Cl N2 O4

Relative stereochemistry.



CM 2

CRN 127-19-5
CMF C4 H9 N O




RN 939768-71-5 CAPLUS
CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, trans-, compd. with pyridine (1:1) (CA INDEX NAME)

CM 1

CRN 908570-13-8
CMF C18 H21 Cl N2 O4

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N




RN 939768-72-6 CAPLUS
CN Cyclobutanecarboxylic acid, 3-[[8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazoline]-5'-yl]oxy]-, trans-, compd. with tetrahydrofuran (1:1) (CA INDEX NAME)

CM 1

CRN 908570-13-8
CMF C18 H21 Cl N2 O4

Relative stereochemistry.



CM 2

CRN 109-99-9
CMF C4 H8 O




RN 939768-73-7 CAPLUS
CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinolin]-5'-yl)oxy]-, trans-, compd. with 1,1'-sulfinylbis[methane] (1:?) (CA INDEX NAME)

CM 1

CRN 908570-13-8
CMF C18 H21 Cl N2 O4


Relative stereochemistry.



CM 2

CRN 67-68-5


CMF C2 H6 O S



IT 939768-67-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of spiro-cyclic quinazoline derivs. as phosphodiesterase
 inhibitors and antiviral agents)

RN 939768-67-9 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-fluoro-5'-hydroxy-
 (CA INDEX NAME)

IT 460346-02-5P 460346-10-5P 674336-39-1P

908570-15-0P 908570-16-1P 908570-18-3P

908570-19-4P 939768-52-2P 939768-53-3P

939768-54-4P 939768-55-5P 939768-56-6P

939768-57-7P 939768-61-3P 939768-62-4P

939768-63-5P 939768-66-8P 939768-69-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of spiro-cyclic quinazoline derivs. as phosphodiesterase
 inhibitors and antiviral agents)

RN 460346-02-5 CAPLUS


CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-methoxy-

(CA INDEX NAME)




RN 460346-10-5 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-hydroxy-
(CA INDEX NAME)



RN 674336-39-1 CAPLUS


CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-hydroxy-
(CA INDEX NAME)



RN 908570-15-0 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[[cis-3-
(phenylmethoxy)methyl]cyclobutyl]oxy]- (CA INDEX NAME)


Relative stereochemistry.



RN 908570-16-1 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[[cis-3-(hydroxymethyl)cyclobutyl]oxy]- (CA INDEX NAME)


Relative stereochemistry.



RN 908570-18-3 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[[trans-3-[(phenylmethoxy)methyl]cyclobutyl]oxy]- (CA INDEX NAME)

Relative stereochemistry.




RN 908570-19-4 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[[trans-

3-(hydroxymethyl)cyclobutyl]oxy]- (CA INDEX NAME)


Relative stereochemistry.



RN 939768-52-2 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[[8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazoline]-5'-yl]oxy]-, 1,1-dimethylethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 939768-53-3 CAPLUS


CN Cyclobutanecarboxylic acid, 3-[[8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazoline]-5'-yl]oxy]-, trans-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 908570-13-8

CMF C18 H21 Cl N2 O4


Relative stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 939768-54-4 CAPLUS


CN Cyclobutanecarboxylic acid, 3-[[[8'-fluoro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazoline]-5'-yl]oxy]methyl]-, phenylmethyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 939768-55-5 CAPLUS


CN Cyclobutanecarboxylic acid, 1-[[[8'-fluoro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazoline]-5'-yl]oxy]methyl]-, methyl ester (CA INDEX NAME)



RN 939768-56-6 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[[8'-chloro-2',3'-dihydro-2'-oxospiro[cycloheptane-1,4'(1'H)-quinazoline]-5'-yl]oxy]-, ethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 939768-57-7 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[[8'-chloro-2',3'-dihydro-2'-oxospiro[cyclopentane-1,4'(1'H)-quinazolin]-5'-yl]oxy]-, 1,1-dimethylethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 939768-61-3 CAPLUS


CN Spiro[cyclohexane-1,4'-(1'H)-quinazoline]-8'-carbonitrile,
2',3'-dihydro-5'-[[trans-3-(hydroxymethyl)cyclobutyl]oxy]-2'-oxo- (CA
INDEX NAME)

Relative stereochemistry.




RN 939768-62-4 CAPLUS

CN Spiro[cycloheptane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-methoxy- (CA INDEX NAME)




RN 939768-63-5 CAPLUS

CN Spiro[cycloheptane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-hydroxy- (CA INDEX NAME)



RN 939768-66-8 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-methoxy-
(CA INDEX NAME)




RN 939768-69-1 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-hydroxy-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 460346-10-5


CMF C13 H15 Cl N2 O2



CM 2

CRN 64-19-7


CMF C2 H4 O2



L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:918813 CAPLUS
 DOCUMENT NUMBER: 145:315261
 TITLE: Use of combinations of PDE7 inhibitors and
 alpha-2-delta ligands for the treatment of neuropathic
 pain
 INVENTOR(S): Cox, Peter; Kinloch, Ross Anderson; Maw, Graham Nigel
 PATENT ASSIGNEE(S): Pfizer Limited, UK
 SOURCE: PCT Int. Appl., 101pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006092692	A1	20060908	WO 2006-IB385	20060216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2006241158	A	20060914	JP 2006-52759	20060228
JP 2006241159	A	20060914	JP 2006-53415	20060228
PRIORITY APPLN. INFO.:			GB 2005-4209	A 20050301
			US 2005-675761P	P 20050427
			US 2005-741854P	P 20051202


OTHER SOURCE(S): CASREACT 145:315261
 AB The invention relates to a combination of a phosphodiesterase 7 (PDE7) inhibitor and an alpha-2-delta ligand or their pharmaceutically acceptable salts for use in the treatment of pain, particularly inflammatory, neuropathic, visceral and nociceptive pain. An example of a PDE7 inhibitor is cis-3-[(8'-chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid and an example of an alpha-2-delta ligand is (2S)-2-amino-4-ethyl-2-methylhexanoic acid, syntheses of which are described.
 IT 460346-24-1P 908570-12-7P 908570-13-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (combinations of PDE7 inhibitors and alpha-2-delta ligands for treatment of neuropathic pain)
 RN 460346-24-1 CAPLUS
 CN Butanoic acid, 4-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)



RN 908570-12-7 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, cis- (CA INDEX NAME)


Relative stereochemistry.



RN 908570-13-8 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, trans- (CA INDEX NAME)


Relative stereochemistry.



IT 460346-10-5


RL: RCT (Reactant); RACT (Reactant or reagent)
(combinations of PDE7 inhibitors and alpha-2-delta ligands for treatment of neuropathic pain)

RN 460346-10-5 CAPLUS
CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-hydroxy-
(CA INDEX NAME)




IT 908570-15-0P 908570-16-1P 908570-18-3P
908570-19-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(combinations of PDE7 inhibitors and alpha-2-delta ligands for
treatment of neuropathic pain)
RN 908570-15-0 CAPLUS
CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[[cis-3-
[(phenylmethoxy)methyl]cyclobutyl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 908570-16-1 CAPLUS
CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[[cis-3-
(hydroxymethyl)cyclobutyl]oxy]- (CA INDEX NAME)


Relative stereochemistry.



RN 908570-18-3 CAPLUS

CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-[[trans-3-[(phenylmethoxy)methyl]cyclobutyl]oxy]- (CA INDEX NAME)


Relative stereochemistry.



RN 908570-19-4 CAPLUS

CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-[[trans-3-(hydroxymethyl)cyclobutyl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:



14

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:918625 CAPLUS
 DOCUMENT NUMBER: 145:315008
 TITLE: Preparation of spiro[cyclohexane-1,4'-quinazoline] derivatives for use as PDE7 inhibitors for the treatment of neuropathic pain
 INVENTOR(S): Cox, Peter; Kinloch, Ross Anderson; Maw, Graham Nigel
 PATENT ASSIGNEE(S): Pfizer Limited, UK
 SOURCE: PCT Int. Appl., 108pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006092691	A1	20060908	WO 2006-IB369	20060216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006219643	A1	20060908	AU 2006-219643	20060216
CA 2599662	A1	20060908	CA 2006-2599662	20060216
EP 1855686	A1	20071121	EP 2006-710434	20060216
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2006241159	A	20060914	JP 2006-53415	20060228
KR 2007107099	A	20071106	KR 2007-720010	20070831
MX 200710721	A	20071113	MX 2007-10721	20070831
IN 2007DN07221	A	20071012	IN 2007-DN7221	20070919
CN 101146539	A	20080319	CN 2006-80009067	20070920
PRIORITY APPLN. INFO.:			GB 2005-4209	A 20050301
			US 2005-675761P	P 20050427
			WO 2006-IB369	W 20060216

OTHER SOURCE(S): MARPAT 145:315008
 GI



AB Compds. I-III [Ring B = (un)substituted six-membered aryl or heteroaryl ring; Ring A = (un)substituted spirocycle or spiroheterocycle; X = O or NH, NNH₂, etc.; Y = O, S, NH, etc.; Z = CHNO₂, O, S, etc.; Z1 = H, Me, NH₂, etc.] are disclosed as phosphodiesterase 7 (PDE7) inhibitors for use in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an inhibitor of PDE7. Methods for preparing title compds. are given. Thus, e.g., IV was prepared by substitution of trans-3-[(benzyloxy)methyl]cyclobutyl p-toluenesulfonate (preparation given) with 8'-chloro-5'-hydroxy-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one followed by deprotection and oxidation. In PDE7A inhibition assays, IV demonstrated a Ki value of 1.9 (nM).

IT 908570-12-7P 908570-13-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spiro[cyclohexane-1,4'-quinazoline] derivs. for use as PDE7 inhibitors for the treatment of neuropathic pain)

RN 908570-12-7 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, cis
NAME)


Relative stereochemistry.



RN 908570-13-8 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, trans- (CA INDEX NAME)

Relative stereochemistry.




IT 460346-24-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of spiro[cyclohexane-1,4'-quinazoline] derivs. for use as PDE7 inhibitors for the treatment of neuropathic pain)

RN 460346-24-1 CAPLUS

CN Butanoic acid, 4-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




IT 460346-10-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of spiro[cyclohexane-1,4'-quinazoline] derivs. for use as PDE7
 inhibitors for the treatment of neuropathic pain)

RN 460346-10-5 CAPLUS

CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-hydroxy-
 (CA INDEX NAME)




IT 908570-15-0P 908570-16-1P 908570-18-3P
 908570-19-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of spiro[cyclohexane-1,4'-quinazoline] derivs. for use as PDE7
 inhibitors for the treatment of neuropathic pain)

RN 908570-15-0 CAPLUS

CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-[[cis-3-
 [(phenylmethoxy)methyl]cyclobutyl]oxy]- (CA INDEX NAME)


Relative stereochemistry.



RN 908570-16-1 CAPLUS

CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-[[cis-3-
 (hydroxymethyl)cyclobutyl]oxy]- (CA INDEX NAME)


Relative stereochemistry.



RN 908570-18-3 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[[trans-3-[(phenylmethoxy)methyl]cyclobutyl]oxy]- (CA INDEX NAME)


Relative stereochemistry.



RN 908570-19-4 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[[trans-3-(hydroxymethyl)cyclobutyl]oxy]- (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:689239 CAPLUS
 DOCUMENT NUMBER: 141:332154
 TITLE: Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: optimization of 5,8-disubstituted derivatives
 AUTHOR(S): Bernardelli, Patrick; Lorthiois, Edwige; Vergne, Fabrice; Oliveira, Chrystelle; Mafroud, Abdel-Kader; Proust, Emmanuelle; Pham, Nga; Ducrot, Pierre; Moreau, Francois; Idrissi, Moulay; Tertre, Anita; Bertin, Bernadette; Coupe, Magali; Chevalier, Eric; Descours, Arnaud; Berlizon-Seux, Francoise; Berna, Patrick; Li, Mei
 CORPORATE SOURCE: Pfizer Global Research and Development, Fresnes, 94265, Fr.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(18), 4627-4631
 CODEN: BMCL8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:332154
 GI




AB The optimization of 5,8-disubstituted spirocyclohexane-quinazolinones into potent, selective, soluble PDE7 inhibitors with acceptable in vivo pharmacokinetic parameters is presented. It was also reported that 5'-carboxymethoxy-8'-chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one (I) and 8'-chloro-5'-(2-hydroxyethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one were selected for studies in rat models.

IT 460346-61-6
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]ethyl]glycine and study of its activity as phosphodiesterase (PDE7) inhibitor)

RN 460346-61-6 CAPLUS

CN Glycine, N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 460346-02-5P, 8'-Chloro-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-10-5P, 8'-Chloro-5'-hydroxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-28-5P, 8'-Chloro-5'-(2-hydroxyethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-31-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one derivs. and study of their activity as phosphodiesterase (PDE-7) inhibitors)


RN 460346-02-5 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-methoxy- (CA INDEX NAME)



RN 460346-10-5 CAPLUS


CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-hydroxy- (CA INDEX NAME)



RN 460346-28-5 CAPLUS


CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(2-

hydroxyethoxy)- (CA INDEX NAME)



RN 460346-31-0 CAPLUS


CN Acetonitrile, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)



IT 460346-14-9P, 8'-Chloro-5'-(2-(4-morpholino)ethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-23-0P,
 5'-Carboxymethoxy-8'-chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one
 460346-32-1P, 8'-Chloro-5'-(1H-tetrazol-5-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one
 460346-33-2P, 8'-Chloro-5'-(5-hydroxy-[1,2,4]oxadiazol-3-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one derivs.
 and study of their activity as phosphodiesterase (PDE-7) inhibitors)


RN 460346-14-9 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(2-(4-morpholinyl)ethoxy)- (CA INDEX NAME)




RN 460346-23-0 CAPLUS

CN Acetic acid, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)



RN 460346-32-1 CAPLUS


CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(1H-tetrazol-5-ylmethoxy)- (9CI) (CA INDEX NAME)



RN 460346-33-2 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(2,5-


dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)



IT 460346-15-0P, 8'-Chloro-5'-[2-(dimethylamino)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-16-1P,
 8'-Chloro-5'-(2-aminoethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-18-3P, 8'-Chloro-5'-[2-(methylamino)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-19-4P,
 8'-Chloro-5'-(2-(2-aminoethoxy)ethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-21-8P, 8'-Chloro-5'-(3-(dimethylamino)propoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-26-3P, 8'-Chloro-5'-(3-sulfopropoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-29-6P, 8'-Chloro-5'-(5-ethoxycarbonylfuran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-30-9P, 8'-Chloro-5'-(5-carboxyfuran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-57-0P, 8'-Chloro-5'-(3-(dimethylamino)-2-hydroxypropoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-59-2P, 8'-Chloro-5'-(3-methylamino-2-hydroxypropoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one derivs. and study of their activity as phosphodiesterase (PDE7) inhibitors)

RN 460346-15-0 CAPLUS


CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(2-(dimethylamino)ethoxy]- (CA INDEX NAME)



RN 460346-16-1 CAPLUS


CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 5'-(2-aminoethoxy)-8'-

chloro- (CA INDEX NAME)




RN 460346-18-3 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-(methylamino)ethoxy]- (CA INDEX NAME)




RN 460346-19-4 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 5'-[2-(2-aminoethoxy)ethoxy]-8'-chloro- (CA INDEX NAME)




RN 460346-21-8 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[3-(dimethylamino)propoxy]- (CA INDEX NAME)




RN 460346-26-3 CAPLUS

CN 1-Propanesulfonic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-29-6 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460346-30-9 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]methyl]-(9CI) (CA INDEX NAME)




RN 460346-57-0 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(3-(dimethylamino)-2-hydroxypropoxy)- (CA INDEX NAME)



RN 460346-59-2 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(2-hydroxy-3-(methylamino)propoxy)- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:689238 CAPLUS

DOCUMENT NUMBER: 141:253666

TITLE: Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1

AUTHOR(S): Lorthiois, Edwige; Bernardelli, Patrick; Vergne,

Fabrice; Oliveira, Chrystelle; Mafroud, Abdel-Kader; Proust, Emmanuelle; Heuze, Lamia; Moreau, Francois; Idrissi, Moulay; Tertre, Anita; Bertin, Bernadette; Coupe, Magali; Wrigglesworth, Roger; Descours, Arnaud; Soulard, Patricia; Berna, Patrick

CORPORATE SOURCE: Pfizer Global Research and Development, Fresnes, 94265, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(18), 4623-4626

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:253666


AB The synthesis and SAR studies of spiroquinazolinones as novel PDE7 inhibitors are discussed. The best compds. from the series displayed nanomolar inhibitory affinity and were selective vs. other PDE isoenzymes.

IT 460345-40-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(spiroquinazolinones as PDE7 inhibitors)

RN 460345-40-8 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 6'-methoxy- (CA INDEX NAME)




IT 460345-42-0P 460345-65-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(spiroquinazolinones as PDE7 inhibitors)


RN 460345-42-0 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 7'-methoxy- (CA INDEX NAME)



RN 460345-65-7 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-6'-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:246965 CAPLUS
 DOCUMENT NUMBER: 140:270874
 TITLE: Preparation of spirocondensed quinazolinones as phosphodiesterase inhibitors
 INVENTOR(S): Bernardelli, Patrick; Vergne, Fabrice; Mendes, Chrystelle; Ducrot, Pierre
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1400244	A1	20040324	EP 2002-292275	20020917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2499330	A1	20040401	CA 2003-2499330	20030908
WO 2004026818	A1	20040401	WO 2003-IB3965	20030908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003259496	A1	20040408	AU 2003-259496	20030908
EP 1542694	A1	20050622	EP 2003-797455	20030908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014379	A	20050719	BR 2003-14379	20030908
CN 1681507	A	20051012	CN 2003-822128	20030908
JP 2006501277	T	20060112	JP 2004-537412	20030908
TW 251590	B	20060321	TW 2003-92125477	20030916
US 20040106631	A1	20040603	US 2003-667111	20030917
MX 2005PA02913	A	20050527	MX 2005-PA2913	20050316
NO 2005001695	A	20050405	NO 2005-1695	20050405
PRIORITY APPLN. INFO.:			EP 2002-292275	A 20020917

US 2002-429507P P 20021126
 WO 2003-IB3965 W 20030908

OTHER SOURCE(S):
 GI

MARPAT 140:270874




AB Title compds. I [$m = 1, 2, 3$; $R1 = Me, Cl, Br, F$; $R2 = (un)substituted alkyl, heterocyclic$] were prep'd. for use as inhibitors of PDE-7 (no data). Thus, I [$R1 = Cl$, $R2 = OCH2CH2NHCH2CO2Me$] was treated with aqueous NH3 to give I [$R1 = Cl$, $R2 = OCH2CH2NHCH2CONH2$].

IT 674336-39-1 674336-44-8 674336-59-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of spirocondensed quinazolinones as phosphodiesterase inhibitors)


RN 674336-39-1 CAPLUS

CN Spiro[cyclopentane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-hydroxy-
 (CA INDEX NAME)




RN 674336-44-8 CAPLUS

CN Spiro[cyclopentane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-(2'-hydroxyethoxy)-
 (CA INDEX NAME)




RN 674336-59-5 CAPLUS


CN Glycine, N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclopentane-1,4' (1'H)-quinazolin]-5'-yl)oxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 674336-41-5P 674336-46-0P 674336-51-7P
 674336-53-9P 674336-55-1P 674336-56-2P
 674336-57-3P 674336-58-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of spirocondensed quinazolinones as phosphodiesterase inhibitors)
 RN 674336-41-5 CAPLUS
 CN Spiro[cyclopentane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-[(methylthio)methoxy]- (CA INDEX NAME)




RN 674336-46-0 CAPLUS
 CN Spiro[cyclopentane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-(2-iodoethoxy)- (CA INDEX NAME)




RN 674336-51-7 CAPLUS
 CN Spiro[cyclopentane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-fluoro-5'-methoxy- (CA INDEX NAME)




RN 674336-53-9 CAPLUS
CN Spiro[cyclopentane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-fluoro-5'-hydroxy-
(CA INDEX NAME)




RN 674336-55-1 CAPLUS
CN Spiro[cyclopentane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-fluoro-5'-[3-
(methylthio)propoxy]- (CA INDEX NAME)



RN 674336-56-2 CAPLUS
CN Spiro[cyclopentane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-fluoro-5'-
[(methylthio)methoxy]- (CA INDEX NAME)




RN 674336-57-3 CAPLUS
CN Spiro[cyclopentane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 5'-[[1-
(diphenylmethyl)-3-azetidinyl]oxy]-8'-fluoro- (CA INDEX NAME)



RN 674336-58-4 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 5'-(3-azetidinylloxy)-8'-fluoro- (CA INDEX NAME)



IT 674336-60-8P 674336-61-9P 674336-62-0P


674336-63-1P 674336-64-2P 674336-65-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spirocondensed quinazolinones as phosphodiesterase inhibitors)


RN 674336-60-8 CAPLUS

CN Acetamide, 2-[(2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclopentane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]ethyl)amino]- (9CI) (CA INDEX NAME)




RN 674336-61-9 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[(methylsulfinyl)methoxy]- (CA INDEX NAME)




RN 674336-62-0 CAPLUS

CN Acetamide, N-[2-[(2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclopentane-1,4'(1'H)-quinazolin]-5'-yl)oxy]ethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 674336-63-1 CAPLUS

CN Spiro[cyclopentane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-fluoro-5'-[3-(methylsulfinyl)propoxy]- (CA INDEX NAME)




RN 674336-64-2 CAPLUS

CN Spiro[cyclopentane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-fluoro-5'-[(methylsulfinyl)methoxy]- (CA INDEX NAME)



RN 674336-65-3 CAPLUS

CN Spiro[cyclopentane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-fluoro-5'-[[1-(1H-pyrazol-3-ylmethyl)-3-azetidinyl]oxy]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:754361 CAPLUS

DOCUMENT NUMBER: 137:247713

TITLE: Preparation of spirotricyclic quinoline derivatives and analogs and their use as phosphodiesterase-7 inhibitors

INVENTOR(S): Bernardelli, Patrick; Ducrot, Pierre; Lorthiois, Edwige; Vergne, Fabrice

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076953	A1	20021003	WO 2001-EP3355	20010321
W: US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AP 1699	A	20061231	AP 2003-2857	20010321
W: GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZW				
TW 267509	B	20061201	TW 2002-91104028	20020305

CA 2441313	A1	20020926	CA 2002-2441313	20020318
WO 2002074754	A1	20020926	WO 2002-EP3594	20020318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002304800	A1	20021003	AU 2002-304800	20020318
AU 2002304800	B2	20070830		
EP 1373224	A1	20040102	EP 2002-732544	20020318
EP 1373224	B1	20070718		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300459	A	20040216	EE 2003-459	20020318
HU 2003003637	A2	20040301	HU 2003-3637	20020318
HU 2003003637	A3	20040728		
BR 2002008192	A	20040302	BR 2002-8192	20020318
CN 1498212	A	20040519	CN 2002-806971	20020318
JP 2004529123	T	20040924	JP 2002-573763	20020318
NZ 527847	A	20050624	NZ 2002-527847	20020318
EP 1801106	A2	20070627	EP 2007-104642	20020318
EP 1801106	A3	20070704		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
AT 367381	T	20070815	AT 2002-732544	20020318
ES 2288552	T3	20080116	ES 2002-732544	20020318
US 20020198198	A1	20021226	US 2002-101996	20020319
ZA 2003006601	A	20040825	ZA 2003-6601	20030825
IN 2003DN01358	A	20070112	IN 2003-DN1358	20030826
BG 108181	A	20040930	BG 2003-108181	20030917
NO 2003004187	A	20031015	NO 2003-4187	20030919
MX 2003PA08485	A	20031208	MX 2003-PA8485	20030919
US 20040214843	A1	20041028	US 2004-852404	20040524
US 7214676	B2	20070508		
US 20070049558	A1	20070301	US 2006-551687	20061020
AU 2007240176	A1	20080103	AU 2007-240176	20071207
PRIORITY APPLN. INFO.:			WO 2001-EP3355	A 20010321
			AU 2002-304800	A3 20020318
			EP 2002-732544	A3 20020318
			WO 2002-EP3594	W 20020318
			US 2002-101996	B1 20020319
			US 2004-852404	A3 20040524

OTHER SOURCE(S):
GI

MARPAT 137:247713



AB Title compds. I [X1-4 = N provided that not more than two of X1-4 simultaneously represent N; C-R1; R1 = Q1, alk(en/yn)yl, Q1 = H, halo, CN, NO₂, SO₃H, etc.; when X1-2 both represent C-R1, the 2 substituents R1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring; X is O, NR9; R9 = H, CN, OH, NH₂, alk(en/yn)yl; Y = O, S, NR12; R12 = H, CN, OH, NH₂, alk(en/yn)yl; Z = CH-NO₂, O, S, NR13; R13 = H, CN, OH, NH₂, aryl, heteroaryl, cycloalkyl, etc.; A = cyclohexyl, heterocyclyl, etc. and tautomeric analogs] were prepared. For instance, II was prepared from 2,5-dichlorophenylurea, cyclohexanone and polyphosphoric acid in 7% yield. II had IC₅₀ = 0.014 μM for the PDE7 receptor. I are useful for the treatment of autoimmune diseases, osteoarthritis, etc.


IT 460345-40-8P, 6'-Methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460345-42-0P, 7'-Methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460345-44-2P, 8'-Methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460345-65-7P, 8'-Chloro-6'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE7 inhibitor; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)


RN 460345-40-8 CAPPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 6'-methoxy- (CA INDEX NAME)




RN 460345-42-0 CAPPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 7'-methoxy- (CA INDEX NAME)




RN 460345-44-2 CAPPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-methoxy- (CA INDEX NAME)



RN 460345-65-7 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-6'-methoxy-
(CA INDEX NAME)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:736240 CAPLUS

DOCUMENT NUMBER: 137:247712

TITLE: Preparation of spirotricyclic quinoline derivatives and analogs and their use as phosphodiesterase-7 inhibitors

INVENTOR(S): Bernardelli, Patrick; Ducrot, Pierre; Lorthiois, Edwige; Vergne, Fabrice

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 187 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074754	A1	20020926	WO 2002-EP3594	20020318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002076953	A1	20021003	WO 2001-EP3355	20010321

W: US
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

CA 2441313	A1	20020926	CA 2002-2441313	20020318
AU 2002304800	A1	20021003	AU 2002-304800	20020318
AU 2002304800	B2	20070830		
EP 1373224	A1	20040102	EP 2002-732544	20020318
EP 1373224	B1	20070718		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300459	A	20040216	EE 2003-459	20020318
HU 2003003637	A2	20040301	HU 2003-3637	20020318
HU 2003003637	A3	20040728		
BR 2002008192	A	20040302	BR 2002-8192	20020318
JP 2004529123	T	20040924	JP 2002-573763	20020318
NZ 527847	A	20050624	NZ 2002-527847	20020318
IN 2003DN01358	A	20070112	IN 2003-DN1358	20030826
BG 108181	A	20040930	BG 2003-108181	20030917
NO 2003004187	A	20031015	NO 2003-4187	20030919
MX 2003PA08485	A	20031208	MX 2003-PA8485	20030919
AU 2007240176	A1	20080103	AU 2007-240176	20071207
PRIORITY APPLN. INFO.:				
		WO 2001-EP3355	W	20010321
		AU 2002-304800	A3	20020318
		WO 2002-EP3594	W	20020318

OTHER SOURCE(S): MARPAT 137:247712
 GI



AB Title compds. I [X1-4 = N provided that not more than two of X1-4 simultaneously represent N; C-R1; R1 = Q1, alk(en/yn)yl, Q1 = H, halo, CN, NO₂, SO₃H, etc.; when X1-2 both represent C-R1, the 2 substituents R1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring; X is O, NR₉; R₉ = H, CN, OH, NH₂, alk(en/yn)yl; Y = O, S, NR₁₂; R₁₂ = H, CN, OH, NH₂, alk(en/yn)yl; Z = CH-NO₂, O, S, NR₁₃; R₁₃ = H, CN, OH, NH₂, aryl, heteroaryl, cycloalkyl, etc.; A = cyclohexyl, heterocyclyl, etc. and tautomeric analogs] were prepared. For instance, II was prepared from 2,5-dichlorophenylurea, cyclohexanone and polyphosphoric acid in 7% yield. II had IC₅₀ = 0.014 μM for the PDE7 receptor. I are useful for the treatment of autoimmune diseases, osteoarthritis, etc.

IT 460346-10-5P, 8'-Chloro-5'-hydroxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-11-6P, 8'-Chloro-5'-hydroxy-6'-iodospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-12-7P, 8'-Chloro-6'-iodo-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-28-5P, 8'-Chloro-5'-(2-hydroxyethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-31-0P, 8'-Chloro-5'-cyanomethoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-37-6P, 6'-(4-Carboxyphenyl)-8'-chloro-5'-


methoxyspiro[cyclohexane-1, 4'-quinazolin]-2'(1'H)-one 460346-60-5P
, 8'-Chloro-5'-[2-(((ethoxycarbonyl)methyl)amino)ethoxy]spiro[cyclohexane-1, 4'-quinazolin]-2'(1'H)-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(PDE7 inhibitor; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)


RN 460346-10-5 CAPLUS

CN Spiro[cyclohexane-1, 4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-hydroxy- (CA INDEX NAME)




RN 460346-11-6 CAPLUS

CN Spiro[cyclohexane-1, 4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-hydroxy-6'-ido- (CA INDEX NAME)




RN 460346-12-7 CAPLUS

CN Spiro[cyclohexane-1, 4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-methoxy-6'-ido- (CA INDEX NAME)




RN 460346-28-5 CAPLUS


CN Spiro[cyclohexane-1, 4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(2-hydroxyethoxy)- (CA INDEX NAME)




RN 460346-31-0 CAPLUS
CN Acetonitrile, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-37-6 CAPLUS
CN Benzoic acid, 4-(8'-chloro-2',3'-dihydro-5'-methoxy-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-6'-yl)- (9CI) (CA INDEX NAME)




RN 460346-60-5 CAPLUS
CN Glycine, N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxyethyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 460345-40-8P, 6'-Methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460345-42-0P, 7'-Methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460345-44-2P, 8'-Methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460345-65-7P, 8'-Chloro-6'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-02-5P, 8'-Chloro-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-13-8P, 8'-Chloro-6'-cyano-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-14-9P, 8'-Chloro-5'-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-15-0P, 8'-Chloro-5'-(2-dimethylaminoethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-16-1P, 8'-Chloro-5'-(2-aminoethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-18-3P, 8'-Chloro-5'-[2-(methylamino)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-19-4P, 8'-Chloro-5'-[2-(2-aminoethoxy)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-21-8P, 8'-Chloro-5'-(3-(dimethylamino)propoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-22-9P, 8'-Chloro-5'-ethoxycarbonylmethoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-23-0P, 5'-Carboxymethoxy-8'-chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-24-1P, 5'-(3-(Carboxy)propoxy)-8'-chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-26-3P, 8'-Chloro-5'-(3-sulfopropoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-27-4P 460346-29-6P, 8'-Chloro-5'-(5-ethoxycarbonylfuran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-30-9P, 8'-Chloro-5'-(5-carboxyfuran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-32-1P, 8'-Chloro-5'-(1H-tetrazol-5-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-33-2P, 8'-Chloro-5'-(5-hydroxy-[1,2,4]oxadiazol-3-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-36-5P, 8'-Chloro-6'-iodo-5'-(2-(dimethylamino)ethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-38-7P, 6'-(3-Carboxyphenyl)-8'-chloro-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-48-9P, 8'-Chloro-5'-methoxy-6'-[4-[[4-methylpiperazine]carbonyl]phenyl]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-57-0P, 8'-Chloro-5'-(3-dimethylamino-2-hydroxypropoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-59-2P, 8'-Chloro-5'-(3-methylamino-2-hydroxypropoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-61-6P, 8'-Chloro-5'-[2-((carboxy)methyl)amino]ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one hydrochloride 460346-63-8P, 8'-Chloro-5'-(2-((methanesulfonyl)amino)-2-oxoethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-64-9P, 8'-Chloro-5'-[2-[(5-methylisoxazol-3-ylmethyl)amino]ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (PDE7 inhibitor; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)
 RN 460345-40-8 CAPLUS
 CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 6'-methoxy- (CA INDEX NAME)




RN 460345-42-0 CAPLUS
CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 7'-methoxy- (CA INDEX NAME)



RN 460345-44-2 CAPLUS
CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-methoxy- (CA INDEX NAME)




RN 460345-65-7 CAPLUS
CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-6'-methoxy- (CA INDEX NAME)




RN 460346-02-5 CAPLUS
CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-methoxy-

(CA INDEX NAME)




RN 460346-13-8 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazoline]-6'-carbonitrile,
8'-chloro-2',3'-dihydro-5'-methoxy-2'-oxo- (CA INDEX NAME)




RN 460346-14-9 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 460346-15-0 CAPLUS


CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)




RN 460346-16-1 CAPLUS
CN Spiro[cyclohexane-1, 4' (1'H)-quinazolin]-2' (3'H)-one, 5'-(2-aminoethoxy)-8'-chloro- (CA INDEX NAME)



RN 460346-18-3 CAPLUS
CN Spiro[cyclohexane-1, 4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-[2-(methylamino)ethoxy]- (CA INDEX NAME)




RN 460346-19-4 CAPLUS
CN Spiro[cyclohexane-1, 4' (1'H)-quinazolin]-2' (3'H)-one, 5'-[2-(2-aminoethoxy)ethoxy]-8'-chloro- (CA INDEX NAME)




RN 460346-21-8 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[3-(dimethylamino)propoxy]- (CA INDEX NAME)




RN 460346-22-9 CAPLUS

CN Acetic acid, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460346-23-0 CAPLUS

CN Acetic acid, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-24-1 CAPLUS

CN Butanoic acid, 4-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-26-3 CAPLUS

CN 1-Propanesulfonic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-27-4 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]- (CA INDEX NAME)




RN 460346-29-6 CAPLUS

CN 2-Furancarboxylic acid, 5-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 460346-30-9 CAPLUS

CN 2-Furancarboxylic acid, 5-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 460346-32-1 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(1H-tetrazol-5-ylmethoxy)- (9CI) (CA INDEX NAME)




RN 460346-33-2 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)




RN 460346-36-5 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[(2-(dimethylamino)ethoxy)-6'-ido- (CA INDEX NAME)




RN 460346-38-7 CAPLUS

CN Benzoic acid, 3-(8'-chloro-2',3'-dihydro-5'-methoxy-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-6'-yl)- (9CI) (CA INDEX NAME)




RN 460346-48-9 CAPLUS

CN Piperazine, 1-[4-(8'-chloro-2',3'-dihydro-5'-methoxy-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-6'-yl)benzoyl]-4-methyl- (9CI)
(CA INDEX NAME)




RN 460346-57-0 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[3-(dimethylamino)-2-hydroxypropoxy]- (CA INDEX NAME)




RN 460346-59-2 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-hydroxy-3-(methylamino)propoxy]- (CA INDEX NAME)




RN 460346-61-6 CAPLUS
CN Glycine, N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 460346-63-8 CAPLUS
CN Acetamide, 2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 460346-64-9 CAPLUS
CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-[(5-methyl-3-isoxazolyl)methyl]amino]ethoxy- (CA INDEX NAME)



IT 460346-17-2P, 8'-Chloro-5'-(2-(methanesulfonyl)ethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-20-7P
 460346-25-2P 460346-34-3P, 8'-Chloro-5'-(N-hydroxycarbamimidoylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one
 460346-58-1P, 8'-Chloro-5'-(oxiran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)

RN 460346-17-2 CAPLUS


CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(2-(methylsulfonyl)ethoxy)- (CA INDEX NAME)



RN 460346-20-7 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]ethoxy]ethyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 460346-25-2 CAPLUS

CN Butanoic acid, 4-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460346-34-3 CAPLUS

CN Ethanimidamide, 2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 460346-58-1 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-(oxiranylmethoxy)- (9CI) (CA INDEX NAME)




IT 460346-35-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)

RN 460346-35-4 CAPLUS

CN Ethanimidamide, 2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]-N-[(ethoxycarbonyl)oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

10/ 667,111

(FILE 'HOME' ENTERED AT 10:41:38 ON 23 APR 2008)

FILE 'REGISTRY' ENTERED AT 10:42:15 ON 23 APR 2008
L1 STRUCTURE uploaded
L2 5 S L1
L3 87 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:42:56 ON 23 APR 2008
L4 8 S L3

=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL
SESSION
FULL ESTIMATED COST ENTRY 44.08 222.65
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
SESSION
CA SUBSCRIBER PRICE ENTRY -6.40 -6.40

STN INTERNATIONAL LOGOFF AT 10:43:35 ON 23 APR 2008